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Two suspected hantavirus pulmonary syndrome (HPS) cases
from Bolivia occurred in May and July 2000 and were con-
firmed by enzyme-linked immunosorbent assay (ELISA)-
ANDES using N-Andes recombinant antigen serology. Clot
RNAs from the two patients were subjected to reverse tran-
scription–polymerase chain reaction (PCR) amplification and
sequencing. We describe two characterized cases of HPS.
One was caused by infection with Bermejo virus and the other
with Andes Nort viral lineage, both previously obtained from
Oligoryzomys species. This is the first report of molecular iden-
tification of a human hantavirus associated with Bermejo virus.
antaviruses cause hemorragic fever with renal syndrome
(HFRS) in Eurasia and hantavirus pulmonary syndrome
(HPS) in the Americas. Infection occurs primarily by the res-
piratory route via aerosolized virus in rodent excreta. Field
investigations have identified sigmodontine rodents as the host
of the respiratory hantaviruses. HPS cases have been reported
in several American countries during the last 8 years including
Argentina, Bolivia, Brazil, Canada, Chile, Panama, Paraguay,
United States, and Uruguay (1-5). Andes virus (ANDV) has
been responsible for most of the >400 cases recorded in
Argentina, Chile, and Uruguay; Oligoryzomys is the predomi-
nant rodent carrier. A different genus, Calomys laucha, was
responsible for most cases in Paraguay associated with Laguna
Negra virus (LNV) (6). Several additional hantaviruses have
been detected in rodents in the Americas but have yet to be
associated with human disease. Cases of HPS shown to be
caused by ANDV (Andes Nort lineage) have been reported in
northern Argentina in the Salta and Jujuy Provinces. No cases
have been reported previously in Bolivia except in a Chilean
HPS patient who was suspected of having acquired the infec-
tion during extensive travel in Bolivia prior to onset of illness
in 1997. The viral characterization revealed an LNV variant
that was 15% at the nucleotide level and identical at the
deduced amino acid level relative to LNV (6). Molecular tech-
niques have aided in the testing of Bolivian specimens from a
museum collection and allowed the identification of a hantavi-
rus named Rio Mamore virus (RIOM) from Oligoryzomys
microtis.  RIOMV has not been associated with human cases
yet (7).
In 2000, a total of six male patients in Bolivia (15 to 49
years) were serologically confirmed to have HPS; five died.
Five out of the six cases occurred between April and July; the
sixth case occurred in November. All the patients lived and
worked in rural areas in a 70-km ratio around Bermejo,
although it was not clear whether one of them (Patient 2) was
infected in Argentina or in Bolivia. In addition, two HPS cases
were previously reported in Bolivia, one in June 1998 and the
other in October 1999. 
Case Reports
Patient 1
On May 18, 2000, a 49-year-old man from Bermejo,
Bolivia, who worked as a woodcutter in San Telmo, had a
onset of HPS symptoms. Seven days later he was hospitalized
at the San Vicente de Paul Hospital and his case was con-
firmed by enzyme-linked immunosorbent assay (ELISA)-
ANDES specific immunoglobulin(Ig) M and immunoglobu-
lin(Ig) G test (8). The patient survived. He had respiratory dis-
tress with bilateral interstitial infiltrates. Initial laboratory
results were as follows: serum creatinine 1.4 mg/dL, platelets
50,000/µL, hematocrit 46%, arterial O2 pressure (PaO2) 50mm
Hg, arterial CO2 pressure (PaCO2) 32mm Hg, leukocytes
6,700 /mm3, urea 0.36 g/L, bilirubin 0.52. mg/100 mL. Labo-
ratory results 4 days after he was hospitalized were as follows:
hematocrit 46%, 46.8%, 48%, 43%; platelets/mm3 50,000,
32,000, 30,000, and 128,000; and white blood cells/mm3
6,700, 15,400, 20,700, and 18,300. 
Patient 2
In July 2000, a 20-year-old man from Bermejo was admit-
ted to the San Vicente de Paul Hospital 4 days after symptoms
began; a preliminary diagnosis of HPS was made. The
patient’s condition deteriorated rapidly, showing respiratory
compromise with bilateral interstitial infiltrates and renal com-
promise with oliguria. Laboratory results were as follows:
serum creatinine 2.3 mg/dL, lactic dehydrogenase (LDH) 572
IU/L, platelets 26,000 /µL, hematocrit 71%, PaO2 73, PaCO2
35, and leukocytes 64,300 /µL. The patient died the same day
he was hospitalized. HPS was confirmed by ELISA-ANDES-
specific IgM and IgG test. Although the patient lived in
Bolivia, he worked as a muleteer in Rio Blanco River in Salta
Province, Argentina for 2 months and came back to Bolivia 3
weeks before his illness.
The Study
Clot samples from the two patients were used to prepare
RNA with an RNA matrix (RNAid kit, BIO101, La Jolla, CA).
The RNA was subjected to reverse transcription-polymerase
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chain reaction (PCR) amplification by nested or heminested
reactions. Synthesized DNA products were separated on agar-
ose gels, gel-purified, and directly sequenced with an ABI 377
sequencer. Three cDNA products were produced, allowing
generation of nucleotide (nt) sequences of 289 nt in length for
an S segment region encoding the most conserved region of
the nucleoprotein (N), and 243 nt and 226 nt in length for two
M segment regions of G1 and G2, respectively. The nucleotide
sequences were determined and compared with known han-
taviruses (Table). Sequence identity differences of 3.3% and
1.2% were seen at the nucleotide and amino acid levels respec-
tively, when the G1 fragment sequence of Patient 1 was com-
pared with those of other viral sequences associated with cases
in North Argentina. Genetic analysis showed that Patient 1’s
viral sequence belonged to the Andes Nort lineage character-
ized previously (2,4). The hantavirus in Patient 2 was clearly
identified as Bermejo virus, previously detected in one O. cha-
coensis captured in Orán City, Salta (2). We ruled out labora-
tory DNA contamination since this was the first available
sample of RNA virus in our hands. Viral G1 fragment
sequence from this patient showed 100% nucleotide identity
compared with the Bermejo virus. Nucleotide and amino acid
differences of 13.2% to 24.3% and 3.7% to 8.6%, respectively,
were seen when the G1 viral fragment from Patient 2 was
related with the more distantly ANDV and closely related lin-
eages including Andes Nort, Andes Sout, and the three differ-
ent Andes Cent lineages (4). To provide more information on
the genetics of Bermejo virus, a highly variable fragment of
the M segment (nt 88 to 442) was amplified and sequenced
(GenBank accession number AF442564). Nucleotide and
amino acid comparison of this fragment between Patient 2 and
Andes Nort lineage showed a divergence of 17.2% and 9.3%,
respectively. Additionally, a divergence of 6.2% and 0% in the
S conserved fragment of Patient 2 and Andes Nort lineage at
the nucleotide and amino acid level, respectively, was
observed. Unfortunately, homologous fragment sequences
from Bermejo virus were not available. Maximum parsimony
phylogenetic analysis of the G1 fragment sequences of the two
patients and other published hantavirus sequences showed the
expected clusters between the viral sequence detected in
Patient 1 and Andes Nort lineage virus and the viral sequence
in Patient 2 and Bermejo virus (data not shown).
In previous studies, O. chacoensis was tentatively impli-
cated as the predominant rodent reservoir for Bermejo virus;
however, the sample size was too small since Bermejo virus
was identified in only 1 rodent (2). Specific cases of HPS were
not linked to the occurrence of the Bermejo virus-infected
rodent at the presumed site of infection. Moreover, Andes Nort
lineage was previously characterized in one rodent (O. flave-
scens), two rodents (O. chacoensis) (9), and two rodents (O.
longicaudatus) (2). Whether the viruses responsible for the
infection in our report were harbored by any particular Oligo-
ryzomys species is now being investigated.
Molecular and epidemiologic data showed the presence of
Andes Nort lineage circulating in Bolivia. Considering that the
incubation period was estimated to be 19.5 days (4) and since
Patient 2 returned from Argentina 21 days before the onset of
disease, in which country the infection occurred was unclear.
This is the first report of molecular identification of a human
hantavirus associated with Bermejo virus.
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0 1,2 1,3 0 7,4 NA — — — NA 21 14,2 13,2 NA NA 14,2 NA NA 16,6 23,1 17,7
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